Mouse Monoclonal Indoleamine 2, 3-dioxygenase antibody. Suitable for WB, IHC-P, ICC/IF and reacts with Human, African green monkey samples. Cited in 4 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human IDO1.
pH: 7.3
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol (glycerin, glycerine), 1% BSA
WB | IHC-P | ICC/IF | |
---|---|---|---|
Human | Tested | Tested | Expected |
African green monkey | Expected | Expected | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/4000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species African green monkey | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/150 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species African green monkey | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species African green monkey | Dilution info 1/100 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Select an associated product type
Catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway (PubMed:17671174). Involved in the peripheral immune tolerance, contributing to maintain homeostasis by preventing autoimmunity or immunopathology that would result from uncontrolled and overreacting immune responses (PubMed:25691885). Tryptophan shortage inhibits T lymphocytes division and accumulation of tryptophan catabolites induces T-cell apoptosis and differentiation of regulatory T-cells (PubMed:25691885). Acts as a suppressor of anti-tumor immunity (PubMed:14502282, PubMed:23103127, PubMed:25157255, PubMed:25691885). Limits the growth of intracellular pathogens by depriving tryptophan (PubMed:25691885). Protects the fetus from maternal immune rejection (PubMed:25691885).
IDO, INDO, IDO1, IDO-1
Mouse Monoclonal Indoleamine 2, 3-dioxygenase antibody. Suitable for WB, IHC-P, ICC/IF and reacts with Human, African green monkey samples. Cited in 4 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human IDO1.
pH: 7.3
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol (glycerin, glycerine), 1% BSA
Purified from cell culture supernatant by affinity chromatography
Indoleamine 2 3-dioxygenase (IDO) also known as IDO1 is an enzyme involved in the catabolism of tryptophan to kynurenine. It weighs approximately 45 kDa and it is an important target in immunoregulatory processes. IDO is highly expressed in antigen-presenting cells such as dendritic cells and macrophages as well as in various tumor cells where it helps modulate immune responses. This enzyme can also be measured by using assays like IDO ELISA.
IDO plays a role in immune response regulation by degrading tryptophan an essential amino acid needed for T-cell proliferation. The depletion of tryptophan and the accumulation of its metabolites such as kynurenine cause immunosuppressive effects within the tissue microenvironment. While IDO functions mostly as a standalone enzyme its activity influences the cellular surroundings by altering the balance of local immune reactions.
IDO integrates into the tryptophan metabolism pathway and is important in the kynurenine pathway. Through this pathway it maintains immune homeostasis and cell defense mechanisms. Proteins like kynureninase and kynurenine 3-monooxygenase also participate in the same metabolic processes which further extend the effects of tryptophan metabolism on immune cell behavior.
IDO is linked with cancer and chronic inflammatory conditions. In cancer elevated IDO expression suppresses anti-tumor immunity aiding tumor cells to evade immune surveillance. It also plays a role in autoimmune disorders by regulating excessive immune activity. During cancer progression IDO often works in conjunction with immune checkpoint proteins like PD-L1 which further enhances its immunosuppressive capabilities within the tumor microenvironment.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ab156787 was shown to react with Indoleamine 2, 3-dioxygenase in treated wild-type A549 cells in Western blot with no signal observed in treated IDO1 knockout cell line Human IDO1 (Indoleamine 2, 3-dioxygenase) knockout A549 cell line ab266949 (IDO1 knockout cell lysate ab256948). Wild-type A549 and IDO1 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with ab156787 and Anti-alpha Tubulin antibody [EP1332Y] - Loading Control ab52866 (Rabbit anti-alpha Tubulin antibody [EP1332Y]) overnight at 4 °C at a 1 in 4000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.
All lanes: Western blot - Anti-Indoleamine 2, 3-dioxygenase antibody [OTI1A3] (ab156787) at 1/4000 dilution
Lane 1: Wild-type A549 Vehicle Control IFN gamma (0 ng/ml, 48 h) cell lysate at 20 µg
Lane 2: Wild-type A549 Treated IFN gamma (25 ng/ml, 48 h) cell lysate at 20 µg
Lane 2: Western blot - Human IDO1 (Indoleamine 2, 3-dioxygenase) knockout A549 cell line (Human IDO1 (Indoleamine 2, 3-dioxygenase) knockout A549 cell line ab266949)
Lane 3: IDO1 knockout A549 Vehicle Control IFN gamma (0 ng/ml, 48 h) cell lysate at 20 µg
Lane 4: IDO1 knockout A549 Treated IFN gamma (25 ng/ml, 48 h) cell lysate at 20 µg
Lane 5: SK-OV-3 cell lysate at 20 µg
Lane 6: MCF7 cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 45 kDa
Observed band size: 40 kDa
Immunohistochemical analysis of paraffin-embedded Human kidney carcinoma tissue labeling Indoleamine 2, 3-dioxygenase with ab156787 at 1/150 dilution.
All lanes: Western blot - Anti-Indoleamine 2, 3-dioxygenase antibody [OTI1A3] (ab156787) at 1/4000 dilution
Lane 1: HEK293T cell lysate transfected with pCMV6-ENTRY control at 5 µg
Lane 2: HEK293T cell lysate transfected with pCMV6-ENTRY Indoleamine 2, 3-dioxygenase cDNA at 5 µg
Predicted band size: 45 kDa
Immunofluorescent analysis of COS7 cells transiently transfected with pCMV6-ENTRY Indoleamine 2, 3-dioxygenase, labeling Indoleamine 2, 3-dioxygenase with ab156787 at 1/100 dilution.
Immunohistochemical analysis of paraffin-embedded Human lymph node tissue labeling Indoleamine 2, 3-dioxygenase with ab156787 at 1/150 dilution.
Immunohistochemical analysis of paraffin-embedded Human lymphoma tissue labeling Indoleamine 2, 3-dioxygenase with ab156787 at 1/150 dilution.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com